Alembic Pharma is planning to launch over 20 products in the current financial year (FY24), with a focus on oral solids, injectables, and derma segments.
Revenues grew 8% to Rs.1595 crore in Q2FY24 compared to Rs 1475 crore last year. The earnings before interest, tax, depreciation and amortization (EBITA) declined 6% YoY to Rs 218 crore. The EBITDA margins stood at 14% in Q2FY24.
Alembic Pharma has reported a Q1 net profit of INR 121 crore, up from a net loss of INR 66 crore YoY, led by increased sales growth across its segments. The Indian branded business recorded a 9% YoY growth to INR 524 crore, while US generics saw 6% YoY growth to INR 354 crore.
Alembic Pharma share slips 5% after Q4 earnings
For FY21, the company posted a net profit of Rs 1178 crore compared to Rs 829 crore in the previous year, up 42 per cent
BusinessToday.In | May 5, 2021 | Updated 15:49 IST
Representative Image
Share of Alembic Pharma declined over 5 per cent in early trade today after the company reported earnings for the quarter ended March 2021. The stock hit an intraday low of Rs 948 and an intraday high of Rs 1,003.
The company reported a net profit of Rs 251 crore for Q4 FY21 compared to Rs 225 crore for the corresponding quarter of the previous year, an increase of 11.5 per cent.